Natera | Prospera - Our Research | Natera

Prospera transplant assessment test - precision for critical decisions when the stakes are high

Prospera precision. Setting a new standard in transplant rejection assessment

Experts in cell-free DNA. Optimized for transplant assessment.

Setting a new standard through research

Best-in-class transplant care depends on best-in-class assessment. Prospera is the most advanced cfDNA solution for assessing transplant rejection—reinforced by ongoing research efforts:

Sigdel et al Clinical Validation, Published in 2019

  • Conducted with the University of California, San Francisco

  • Largest biopsy-matched study conducted in renal transplantation assessing the use of cell-free DNA

  • The first to publish performance of cell-free DNA testing in subclinical, surveillance setting

ProActive Registry Study Now Enrolling

  • Largest clinical utility study evaluating cell-free DNA; includes more than 3,000 kidney transplants studied for three years

  • Long-term assessment of high-risk recipients for up to 5 years post-transplantation

  • Personalized transplant management protocols using cell-free DNA data

Research with Molecular Microscope Diagnostic System (MMDx) Now Enrolling

  • Global, prospective multicenter study under the leadership of Dr. Philip Halloran

  • 300 patients to be comprehensively evaluated with clinical information, cell-free DNA measures, biopsies, molecular microscope, evaluations, and donor-specific antibodies (DSA)

  • Integrated data analysis to better inform non-invasive and interventional management in kidney transplantation

Contact Us

References

  1. Altuğ Y, Liang N, Ram R, et al. Analytical validation of a single-nucleotide polymorphism-based donor-derived cell-free DNA assay for detecting rejection in kidney transplant patients. Transplantation, 2019
  2. Sigdel TK, Archila FA, Constantin T, et al. Optimizing detection of kidney transplant injury by assessment of donor-derived cell-free DNA via massively multiplex PCR. J Clin Med. 2019;8(1):19.
  3. Grskovic M, Hiller DJ, Eubank LA, et al. Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients. J Mol Diagn. 2016;18(6):890-902.
  4. Bloom RD, Bromberg JS, Poggio ED, et al. Cell-free DNA and active rejection in kidney allografts. J Am Soc Nephrol. 2017;28(7):2221-2232. doi: 10.1681/ASN.2016091034.
  5. Huang, et al. Early clinical experience using donor‐derived cell‐free DNA to detect rejection in kidney transplant recipients. Transplantation. 2019, doi: 10.1111/ajt.15289
  6. Stegall et al, Through a Glass Darkly: Seeking Clarity in Preventing Late Kidney Transplant Failure, J Am Soc Nephrol. 2015; 26 (1):20-9
  7. Lamb et al, Long-term renal allograft survival in the United States: a critical reappraisal, Am J of Transplantation. 2011; Mar;11(3):450-62.5.
  8. Organ Donation Statistics. U.S. Department of Health and Human Services. U.S. Government Information on Organ Donation and Transplantation. www.organdonor.gov. Published March 31, 2016.
  9. Kidney Disease Statistics for the United States. National Institute of Diabetes and Digestive and Kidney Diseases. www.niddk.nih.gov. Published Dec. 1, 2016.
Back to Top